Benzinga | Feb 8, 2021 06:51AM EST

NovaBay CEO Issues Letter to Stockholders

NovaBay Pharmaceuticals (NYSE:NBY) issued the following Letter to Stockholders:

To My Fellow Stockholders:

NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: Avenova(r), the premier antimicrobial lid and lash spray, and CelleRx(r) Clinical Reset, a breakthrough product that marked our entry into a new beauty category late last year. I'm excited to announce that we will soon expand consumer access to both products to brick-and-mortar retail stores. Avenova will be available at CVS stores, one of the nation's largest retail chains, and CelleRx Clinical Reset will be available to consumers in the U.S. and China through select luxury retailers.

Among our corporate priorities for the year, we are also actively seeking new products and line extensions in the large ophthalmic and skincare markets. Our experienced commercial organization, improved balance sheet and established industry relationships give us confidence that now is the opportune time to leverage these assets to generate new sources of revenue to increase stockholder value.